Skip to main content

Table 3 Proposed list of domains and domain items for round 1 of the eDelphi questionnaire

From: TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries

Domains

Domain items

Demographics

Social history

Marital history

Past AE treatments

Previous topical treatments for AE

Previous day hospital care treatments for AE

Previous hospitalisation for AE

Previous structured education programme for AE

Current AE treatments

Topical treatments

Allergy test results

Delayed contact hypersensitivity patch test

Atopy patch test

Double-blind, placebo-controlled food challenge

Skin-prick testing to foods or aeroallergens

Chronic (inflammatory) comorbidities

Inflammatory bowel disease

Rheumatoid arthritis

Diabetes mellitus

Smoking/alcohol/recreational drug history

Smoking history

Alcohol intake

Recreational drug history (soft drugs)

Current concomitant medication (i.e. other than specific AE medication

Antihistamines, oral or topical

Topical antibiotics

Oral antibiotics

Allergic rhinoconjunctivitis medication

Asthma medication

Baseline physical examination

Fitzpatrick skin type

Weight and height for BMI calculation

Blood pressure

Body temperature

Chest (lung) auscultation

Heart auscultation

Lymph node palpation (axillary and inguinal)

Skin examination

Baseline physician and patient reported domains

Physician-assessed clinical signs, e.g. EASI or SCORAD score

Investigator/physician global assessment, e.g. IGA

Patient-reported symptoms, e.g. POEM, itch or sleep score

Patient global assessment, e.g. PGA

Generic quality of life score

Dermatology-specific quality of life score

AE-specific quality of life score

Patient-reported satisfaction with AE care received

Baseline investigations and assessments

Blood testing for past/current tuberculosis

Chest radiograph

Hepatitis B status

Hepatitis C status

Human immunodeficiency virus (HIV) status

Varicella zoster virus (VZV) immune status

Pregnancy

Monitoring P3NP in case of methotrexate use in adults

Evaluating TPMT level prior to azathioprine use

Collection of medical photographs to monitor disease extent

Baseline biorepository samples

Collection of blood for biomarkers, e.g. TARC

Collection of DNA (blood or saliva) for filaggrin analysis

Collection of biomaterials, e.g. DNA, PBMC or skin biopsy, for a biorepository

Baseline management

Reasons for choosing specific treatment (systemic or phototherapy)

Routine recording of relative contraindication(s) for selected treatment

Follow-up general questions

Minimum follow-up frequency for registry data entry, once stable therapeutic dose has been reached:

 A. 2 months

 B. 3 months

 C. 4 months

 D. 5 months

 E. 6 months

Minimum follow-up frequency for registry data entry, after stopping photo- or systematic therapy:

 A. 3 months

 B. 6 months

 C. Annually

 D. No follow-up

Follow-up physical examination

Weight and height for BMI calculation

Blood pressure

Body temperature

Chest (lung) auscultation

Heart auscultation

Lymph node palpation (axillary and inguinal)

Skin examination

Follow-up physician- and patient-reported domains

Physician-assessed clinical signs, e.g. EASI or SCORAD score

Investigator/physician global assessment, e.g. IGA

Patient-reported symptoms, e.g. POEM, itch or sleep score

Patient global assessment, e.g. PGA

Generic quality of life score

Dermatology-specific quality of life score

AE-specific quality of life score

Reporting of disease control, e.g. flares, fully controlled weeks, by physician

Reporting of disease control, e.g. flares, fully controlled weeks, by patient

Adherence to treatment between appointments

Patient-reported satisfaction with AE care received

Follow-up investigations and assessments

Minimum frequency of safety investigations:

 A. 6 weeks

 B. 8 weeks

 C. 10 weeks

 D. 12 weeks

 E. 14 weeks

 F. 16 weeks

Collection of medical photographs to monitor disease extent

Follow-up biorepository samples

Collection of blood for biomarkers, e.g. TARC

Collection of biomaterials, e.g. DNA, PBMC or skin biopsy, for a biorepository

  1. AE atopic eczema, BMI Body Mass Index, DNA deoxyribonucleic acid, EASI Eczema Area and Severity Index, HIV Human Immunodeficiency Virus, IGA Investigator Global Assessment, P3NP procollagen type III N-terminal peptide, PBMC peripheral blood mononuclear cell, PGA Patient Global Assessment, POEM Patient-oriented Eczema Measure, SCORAD SCORing Atopic Dermatitis Index, TARC thymus and activation-regulated chemokine, VZV varicella zoster virus